Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib (Q33774517)

29 July 2017

title

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib (English)

1 reference

chronic lymphocytic leukemia

29 July 2017

0 references

1 reference

1 reference

B Cui

3

0 references

author name string

J Yu

1

1 reference

29 July 2017

L Chen

2

1 reference

29 July 2017

Christina Wu

4

1 reference

29 July 2017

M Y Choi

5

1 reference

29 July 2017

Y Chen

6

1 reference

29 July 2017

L Zhang

7

1 reference

29 July 2017

L Z Rassenti

8

1 reference

29 July 2017

G F Widhopf Ii

9

1 reference

29 July 2017

T J Kipps

10

1 reference

29 July 2017

publication date

1 December 2016

1 reference

29 July 2017

1 reference

29 July 2017

volume

31

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

1333-1339

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

29 July 2017

copyright license

start time

1 December 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Wnt5a-Rac1-NF-κB homeostatic circuitry sustains innate immune functions in macrophages.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Nurture versus nature: the microenvironment in chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

Rho GTPases in cell biology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5462858

B-cell receptor signaling in chronic lymphocytic leukemia.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

Hematopoietic Cell Regulation by Rac1 and Rac2 Guanosine Triphosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

7 January 2021

inferred from DOI database lookup

Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

7 January 2021

inferred from DOI database lookup

Development of novel combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.368

7 January 2021

inferred from DOI database lookup

Ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27904138

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/LEU.2016.368

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference